Search Results - "Lubbert, Michael"

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells by Greve, Gabriele, Schiffmann, Insa, Pfeifer, Dietmar, Pantic, Milena, Schüler, Julia, Lübbert, Michael

“…The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib…”
Get full text

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience by Kreutmair, Stefanie, Pfeifer, Dietmar, Waterhouse, Miguel, Takács, Ferenc, Graessel, Linda, Döhner, Konstanze, Duyster, Justus, Illert, Anna Lena, Frey, Anna-Verena, Schmitt, Michael, Lübbert, Michael

“…Wilms’ tumor 1 (WT1) protein is highly immunogenic and overexpressed in acute myeloid leukemia (AML), consequently ranked as a promising target for novel…”
Get full text

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis by Rettig, Andrés R., Ihorst, Gabriele, Bertz, Hartmut, Lübbert, Michael, Marks, Reinhard, Waterhouse, Miguel, Wäsch, Ralph, Zeiser, Robert, Duyster, Justus, Finke, Jürgen

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially curative for acute myeloid leukemia (AML). The inherent graft-versus-leukemia…”
Get full text

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial by Cicconi, Laura, Platzbecker, Uwe, Avvisati, Giuseppe, Paoloni, Francesca, Thiede, Christian, Vignetti, Marco, Fazi, Paola, Ferrara, Felicetto, Divona, Mariadomenica, Albano, Francesco, Efficace, Fabio, Sborgia, Marco, Di Bona, Eros, Breccia, Massimo, Borlenghi, Erika, Cairoli, Roberto, Rambaldi, Alessandro, Melillo, Lorella, La Nasa, Giorgio, Fiedler, Walter, Brossart, Peter, Hertenstein, Bernd, Salih, Helmut R., Annibali, Ombretta, Wattad, Mohammed, Lubbert, Michael, Brandts, Christian H., Hanel, Mathias, Rollig, Christoph, Schmitz, Norbert, Link, Hartmut, Frairia, Chiara, Fozza, Claudio, Maria D’Arco, Alfonso, Di Renzo, Nicola, Cortelezzi, Agostino, Fabbiano, Francesco, Dohner, Konstanze, Ganser, Arnold, Dohner, Hartmut, Amadori, Sergio, Mandelli, Franco, Voso, Maria Teresa, Ehninger, Gerhard, Schlenk, Richard F., Lo-Coco, Francesco

Get full text

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 -mutated acute myeloid leukemia receiving gemtuzumab ozogamicin by Teich, Katrin, Krzykalla, Julia, Kapp-Schwoerer, Silke, Gaidzik, Verena I, Schlenk, Richard F, Paschka, Peter, Weber, Daniela, Fiedler, Walter, Kühn, Michael W M, Schroeder, Thomas, Mayer, Karin, Lübbert, Michael, Ramachandran, Dhanya, Benner, Axel, Ganser, Arnold, Döhner, Hartmut, Heuser, Michael, Döhner, Konstanze, Thol, Felicitas

Get full text

The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression by Gentle, Ian Edward, Moelter, Isabel, Badr, Mohamed Tarek, Döhner, Konstanze, Lübbert, Michael, Häcker, Georg

“…Mutations in the transcription factor C/EBPα are found in ~10% of all acute myeloid leukaemia (AML) cases but the contribution of these mutations to…”
Get full text

Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors by Heumüller, Anezka, Wehrle, Julius, Stosch, Juliane, Niemöller, Christoph, Bleul, Sabine, Waterhouse, Miguel, Uhl, David, Metzeler, Klaus H., Lübbert, Michael, Duyster, Justus, Finke, Jürgen, Becker, Heiko

Get full text

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab by Shoumariyeh, Khalid, Jung, Johannes, Rassner, Michael, Dold, Sandra Maria, Riebl, Veronika, Pantic, Milena, Herget, Georg, Marks, Reinhard, Lübbert, Michael, Wäsch, Ralph, Engelhardt, Monika

Get full text

Characterization of dna demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome by MUND, Cora, HACKANSON, Björn, STRESEMANN, Carlo, LÜBBERT, Michael, LYKO, Frank

“…Azanucleoside drugs such as 5-azacytidine (Vidaza) and 5-aza-2'-deoxycytidine (decitabine, Dacogen) function as DNA methyltransferase inhibitors in vitro and…”
Get full text

Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction by Niemöller, Christoph, Wehrle, Julius, Riba, Julian, Claus, Rainer, Renz, Nathalie, Rhein, Janika, Bleul, Sabine, Stosch, Juliane M., Duyster, Justus, Plass, Christoph, Lutsik, Pavlo, Lipka, Daniel B., Lübbert, Michael, Becker, Heiko

“…Single-cell multi-omics are powerful means to study cell-to-cell heterogeneity. Here, we present a single-tube, bisulfite-free method for the simultaneous,…”
Get full text

Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients by Stomper, Julia, Meier, Ruth, Ma, Tobias, Pfeifer, Dietmar, Ihorst, Gabriele, Blagitko-Dorfs, Nadja, Greve, Gabriele, Zimmer, Dennis, Platzbecker, Uwe, Hagemeijer, Anne, Schmitt-Graeff, Ingrid, Lübbert, Michael

“…Mutations in the EZH2 gene are recurrently found in patients with myeloid neoplasms and are associated with a poor prognosis. We aimed to characterize genetic…”
Get full text

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS by Miyazaki, Yasushi, Tuechler, Heinz, Sanz, Guillermo, Schanz, Julie, Garcia-Manero, Guillermo, Solé, Francesc, Bennett, John M., Bowen, David, Fenaux, Pierre, Dreyfus, Francois, Kantarjian, Hagop, Kuendgen, Andrea, Malcovati, Luca, Cazzola, Mario, Cermak, Jaroslav, Fonatsch, Christa, Le Beau, Michelle M., Slovak, Marilyn L., Santini, Valeria, Lübbert, Michael, Maciejewski, Jaroslaw, Machherndl-Spandl, Sigrid, Magalhaes, Silvia M.M., Pfeilstöcker, Michael, Sekeres, Mikkael A., Sperr, Wolfgang R., Stauder, Reinhard, Tauro, Sudhir, Valent, Peter, Vallespi, Teresa, van de Loosdrecht, Arjan A., Germing, Ulrich, Haase, Detlef, Greenberg, Peter L.

“…•Japanese MDS patients were younger than Caucasian patients.•Japanese MDS patients had more severe cytopenias and difference in karyotype.•No differences in…”
Get full text

Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy by Morera, Ludovica, Lübbert, Michael, Jung, Manfred

“…The term epigenetics is defined as heritable changes in gene expression that are not due to alterations of the DNA sequence. In the last years, it has become…”
Get full text

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials by Ramadan, Safaa M., Suciu, Stefan, Stevens-Kroef, Marian J. P. L., Willemze, Roelof, Amadori, Sergio, de Witte, Theo, Löwenberg, Bob, Muus, Petra, Labar, Boris, Meert, Liv, de Schaetzen, Gaetan, Meloni, Giovanna, Leone, Giuseppe, Vignetti, Marco, Marie, Jean-Pierre, Lübbert, Michael, Baron, Frédéric

“…We report the outcomes of secondary acute myeloid leukemia (s-AML) patients included in one of 13 European Organisation for Research and Treatment of Cancer…”
Get full text

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG) by Becker, Heiko, Suciu, Stefan, Rüter, Björn Hans, Platzbecker, Uwe, Giagounidis, Aristoteles, Selleslag, Dominik, Labar, Boris, Germing, Ulrich, Salih, Helmut R., Muus, Petra, Pflüger, Karl-Heinz, Hagemeijer, Anne, Schaefer, Hans-Eckart, Fiaccadori, Valeria, Baron, Frédéric, Ganser, Arnold, Aul, Carlo, de Witte, Theo, Wijermans, Pierre W., Lübbert, Michael

“…In the European Organisation for Research and Treatment of Cancer (EORTC)/GMDSSG phase III trial 06011, we compared decitabine (15 mg/m 2 every 8 h for 3 days)…”
Get full text

Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias by KRAUTER, Jürgen, GÖRLICH, Kerstin, OTTMANN, Oliver, LÜBBERT, Michael, DOHNER, Hartmut, HEIT, Wolfgang, KANZ, Lothar, GANSER, Arnold, HEIL, Gerhard

“…In patients with acute myeloblastic leukemia with t(8;21) or inv(16) aberrations (core binding factor [CBF] leukemias), minimal residual disease (MRD) can be…”
Get full text

Quantitative analyses of DAPK1 methylation in AML and MDS by Claus, Rainer, Hackanson, Björn, Poetsch, Anna R., Zucknick, Manuela, Sonnet, Miriam, Blagitko-Dorfs, Nadja, Hiller, Jan, Wilop, Stefan, Brümmendorf, Tim H., Galm, Oliver, Platzbecker, Uwe, Byrd, John C., Döhner, Konstanze, Döhner, Hartmut, Lübbert, Michael, Plass, Christoph

“…Aberrant DNA methylation and concomitant transcriptional silencing of death‐associated protein kinase 1 (DAPK1) have been demonstrated to be key pathogenic…”
Get full text

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine by LÜBBERT, Michael, WIJERMANS, Pierre, KUNZMANN, Regina, VERHOEF, Gregor, BOSLY, Andre, RAVOET, Christophe, ANDRE, Marc, FERRANT, Augustin

“…Decitabine (5-aza-2'-deoxycytidine) acts as a powerful demethylating agent in vitro. Clinically, low-dose decitabine ameliorates cytopenias including induction…”
Get full text

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies by Stomper, Julia, Rotondo, John Charles, Greve, Gabriele, Lübbert, Michael

“…Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able…”
Get full text

Acute myeloid leukemia: Epidemiology and etiology by Deschler, Barbara, Lübbert, Michael

“…Acute myeloid leukemias (AMLs) are infrequent, yet highly malignant neoplasms responsible for a large number of cancer‐related deaths. The incidence has been…”
Get full text